Organisation paid for research Program year 2025 Source: CMS Open Payments

Pharmquest

Neither a doctor nor a teaching hospital

Research payments

$4,931,785

4,061 payments

Through program year 2025, Pharmquest is reported as receiving $4,931,785 in research payments, across 4,061 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$50,249	8
2024	Research	$375,981	423
2023	Research	$658,655	1,307
2022	Research	$660,485	1,224
2021	Research	$1,569,125	742
2020	Research	$1,036,168	123
2019	Research	$581,122	234

Breakdown

Who paid Research payments · program years 2019–2025

Pfizer Inc. $2,556,426 119 payments
Novo Nordisk AS $2,022,622 3,923 payments
AstraZeneca Pharmaceuticals LP $349,666 17 payments
Novartis Pharmaceuticals Corporation $3,000 1 payment
Eli Lilly and Company $71 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $1,899,328 81 payments
A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $652,427 25 payments
Nn9536-4999 $519,848 655 payments
Ex9924-4473 $379,100 1,328 payments
Nn9536-7545 $218,069 486 payments
Nn1436-4478 $212,875 280 payments
Title not available ETESIAN Cardiovascular, Renal and Metabolism CV, Product AZD8233 $133,065 2 payments
Nn9536-4374 $127,110 55 payments
Nn9536-4376 $122,045 37 payments
Nn1250-4252 $104,680 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.